Invesco BLDRS Developed Markets 100 ADR Index Fund

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

    By Mike Benson
  • uploads///Chart  GSK
    Healthcare

    GlaxoSmithKline Stock’s June Performance

    British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GW Pharmaceuticals: Recommendations and Market Capitalization

    Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Revenue Was Flat in Second Quarter

    GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates

    Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Novartis Reports Growth in Q2 2018 Earnings

    Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Sanofi’s Established Prescription Products in 4Q17

    Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.

    By Mike Benson
  • uploads///ABLYNX
    Company & Industry Overviews

    Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform

    Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology.

    By Sarah Collins
  • uploads///BIOVERATIV_TXN_HIGHLIGHTS
    Company & Industry Overviews

    Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights

    On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    GSK Has Emerged as Leading Player in Over-the-Counter Market

    GlaxoSmithKline (GSK) is currently the leader in the 135 billion pound consumer healthcare market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GSK Is Focused on Innovative Assets in Oncology Research Pipeline

    In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    AstraZeneca’s 4Q17 Estimates: Segment Revenues

    AstraZeneca’s (AZN) cardiovascular and metabolics diseases segment’s revenues are expected to decrease in 4Q17 due to lower sales of Crestor and Byetta.

    By Mike Benson
  • uploads///Chart  Ratings
    Earnings Report

    Novartis on the Street: Analyst Ratings and Recommendations

    Novartis (NVS) reported revenues of ~$12.4 billion and EPS (earnings per share) of $1.29 for 3Q17, which represented a growth of 2% in revenues.

    By Mike Benson
  • uploads///q results
    Company & Industry Overviews

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Teva Pharmaceutical plans to increase the prices of certain products in its portfolio since the current prices are cited as unsustainable by the company.

    By Sarah Collins
  • uploads///Analysts
    Company & Industry Overviews

    Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018

    In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s Genzyme Business in 3Q17

    Sanofi’s genzyme business reported revenues of 1.63 billion euros in 3Q17, representing a 12.5% YoY (year-over-year) rise in operating revenues.

    By Mike Benson
  • uploads///Nexium
    Company & Industry Overviews

    How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017

    In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.

    By Daniel Collins
  • uploads///Onglyza
    Company & Industry Overviews

    AstraZeneca’s Anti-Diabetes Drugs Onglyza and Bydureon in 2017

    In 3Q17, AstraZeneca’s (AZN) Onglyza generated revenues of $127.0 million, which reflected an ~25.0% decline on a year-over-year basis

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Performance by Segment in 3Q17

    The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.

    By Mike Benson
  • uploads///Chart  GSK
    Miscellaneous

    What GlaxoSmithKline’s 3Q17 Performance Tells Us

    GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Vaccines Business Expected to Boost Sanofi’s Revenues in 2017

    In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.

    By Margaret Patrick
  • uploads///Hemophilia
    Company & Industry Overviews

    A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

    In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Ophthalmology revenues
    Company & Industry Overviews

    How Does Novartis’s Ophthalmology Portfolio Look?

    In 1H17, Novartis’s (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis.

    By Daniel Collins
  • uploads///New launches
    Company & Industry Overviews

    Why New Generic Products Could Boost TEVA’s Revenue Growth

    In August 2017, Teva Pharmaceutical (TEVA) launched the generic version of Eli Lilly’s (LLY) Axiron.

    By Daniel Collins
  • uploads///Chart  KPP
    Company & Industry Overviews

    Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business

    GlaxoSmithKline’s (GSK) global pharmaceuticals business is a part of the pharmaceuticals segment. It reported revenues of 3.24 billion pounds during 2Q17.

    By Mike Benson
  • uploads///Chart  Consumer
    Earnings Report

    GSK’s 2Q17 Earnings: Consumer Healthcare

    GlaxoSmithKline (GSK) reported flat international revenues at constant exchange rates to 843.0 million pounds during 2Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca Expects Brilinta to Become a Blockbuster Therapy in 2017

    In 1Q17, AstraZeneca’s (AZN) Brilinta reported total revenues of ~$224 million, which is 27% growth year-over-year on a constant currency basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Sanofi Pasteur: Why Human Vaccines Matter

    Sanofi Pasteur, Sanofi’s human vaccines business, reported a 3.7% sequential rise in revenues at constant exchange rates in 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Faslodex Expected to Benefit from FALCON Trial Data

    On March 2, 2016, combination therapy Faslodex and palbociclib was approved by the FDA for HR+ human epidermal growth factor receptor 2 negative (or HER2) metastatic breast cancer.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.